These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 17085669

  • 1. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
    La Rosée P, Jia T, Demehri S, Härtel N, de Vries P, Bonham L, Hollenback D, Singer JW, Melo JV, Druker BJ, Deininger MW.
    Clin Cancer Res; 2006 Nov 01; 12(21):6540-6. PubMed ID: 17085669
    [Abstract] [Full Text] [Related]

  • 2. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [Abstract] [Full Text] [Related]

  • 3. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
    Ohmine K, Nagai T, Tarumoto T, Miyoshi T, Muroi K, Mano H, Komatsu N, Takaku F, Ozawa K.
    Stem Cells; 2003 Apr 01; 21(3):315-21. PubMed ID: 12743326
    [Abstract] [Full Text] [Related]

  • 4. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M, Nguyen TK, Dent P, Grant S.
    Mol Pharmacol; 2007 Sep 01; 72(3):788-95. PubMed ID: 17595328
    [Abstract] [Full Text] [Related]

  • 5. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
    Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, Varticovski L, Dent P, Grant S.
    Cancer Res; 2003 May 01; 63(9):2118-26. PubMed ID: 12727828
    [Abstract] [Full Text] [Related]

  • 6. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T, Ohki M, Wu N, Kagechika H, Miura O.
    Cancer Res; 2009 May 01; 69(9):3927-36. PubMed ID: 19366808
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N, Koschmieder S, Tyagi S, Portero-Robles I, Chromic J, Myloch S, Nürnberger H, Rossmanith T, Hofmann WK, Hoelzer D, Ottmann OG.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [Abstract] [Full Text] [Related]

  • 8. Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
    Pagel JM, Laugen C, Bonham L, Hackman RC, Hockenbery DM, Bhatt R, Hollenback D, Carew H, Singer JW, Press OW.
    Clin Cancer Res; 2005 Jul 01; 11(13):4857-66. PubMed ID: 16000584
    [Abstract] [Full Text] [Related]

  • 9. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS, Liu DS, Dai CW, Li RJ.
    Am J Hematol; 2006 Apr 01; 81(4):242-55. PubMed ID: 16550520
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.
    Oncogene; 2008 Aug 07; 27(34):4678-89. PubMed ID: 18427551
    [Abstract] [Full Text] [Related]

  • 11. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE.
    Oncogene; 2002 Nov 21; 21(53):8075-88. PubMed ID: 12444544
    [Abstract] [Full Text] [Related]

  • 12. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
    Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST.
    Cancer Res; 2003 Sep 15; 63(18):5716-22. PubMed ID: 14522890
    [Abstract] [Full Text] [Related]

  • 13. Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors.
    Radujkovic A, Topaly J, Fruehauf S, Zeller WJ.
    Anticancer Res; 2006 Sep 15; 26(3A):2169-77. PubMed ID: 16827161
    [Abstract] [Full Text] [Related]

  • 14. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
    Jacquel A, Colosetti P, Grosso S, Belhacene N, Puissant A, Marchetti S, Breittmayer JP, Auberger P.
    Oncogene; 2007 Apr 12; 26(17):2445-58. PubMed ID: 17043649
    [Abstract] [Full Text] [Related]

  • 15. Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells.
    Morotti A, Cilloni D, Messa F, Arruga F, Defilippi I, Carturan S, Catalano R, Rosso V, Chiarenza A, Pilatrino C, Guerrasio A, Taulli R, Bracco E, Pautasso M, Baraban D, Gottardi E, Saglio G.
    Cancer; 2006 Mar 01; 106(5):1188-96. PubMed ID: 16444746
    [Abstract] [Full Text] [Related]

  • 16. Effect of lysophosphatidic acid acyltransferase-beta inhibition in acute leukemia.
    Douvas MG, Hogan KN, Ji Y, Hollenback D, Bonham L, Singer JW, Mitchell BS.
    Leuk Res; 2006 Aug 01; 30(8):1027-36. PubMed ID: 16488473
    [Abstract] [Full Text] [Related]

  • 17. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
    Chen R, Gandhi V, Plunkett W.
    Cancer Res; 2006 Nov 15; 66(22):10959-66. PubMed ID: 17108134
    [Abstract] [Full Text] [Related]

  • 18. Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines.
    Desplat V, Belloc F, Lagarde V, Boyer C, Melo JV, Reiffers J, Praloran V, Mahon FX.
    Cancer; 2005 Jan 01; 103(1):102-10. PubMed ID: 15558795
    [Abstract] [Full Text] [Related]

  • 19. Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors.
    Lee SM, Bae JH, Kim MJ, Lee HS, Lee MK, Chung BS, Kim DW, Kang CD, Kim SH.
    J Pharmacol Exp Ther; 2007 Sep 01; 322(3):1084-92. PubMed ID: 17569822
    [Abstract] [Full Text] [Related]

  • 20. Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignancies.
    Springett GM, Bonham L, Hummer A, Linkov I, Misra D, Ma C, Pezzoni G, Di Giovine S, Singer J, Kawasaki H, Spriggs D, Soslow R, Dupont J.
    Cancer Res; 2005 Oct 15; 65(20):9415-25. PubMed ID: 16230405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.